160 related articles for article (PubMed ID: 17765966)
41. GATA1 mutational analysis in chronic myeloid leukaemia.
Halsey C; Fisher C; Strathdee G; Gibson B; Holyoake T; Vyas P; Graham G
Br J Haematol; 2007 May; 137(4):375-6. PubMed ID: 17408401
[No Abstract] [Full Text] [Related]
42. sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia.
Pehlivan M; Sercan Z; Sercan HO
Leuk Res; 2009 Aug; 33(8):1062-7. PubMed ID: 19118898
[TBL] [Abstract][Full Text] [Related]
43. Absence of microsatellite instability during the progression of chronic myelocytic leukemia.
Mori N; Takeuchi S; Tasaka T; Lee S; Spira S; Ben-Yehuda D; Mizoguchi H; Schiller G; Koeffler HP
Leukemia; 1997 Jan; 11(1):151-2. PubMed ID: 9001431
[TBL] [Abstract][Full Text] [Related]
44. Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma.
Lee HS; Kim BH; Cho NY; Yoo EJ; Choi M; Shin SH; Jang JJ; Suh KS; Kim YS; Kang GH
Clin Cancer Res; 2009 Feb; 15(3):812-20. PubMed ID: 19188151
[TBL] [Abstract][Full Text] [Related]
45. The spectrum of adult B-lymphoid leukemias with BCR-ABL: molecular diagnostic, cytogenetic, and clinical laboratory perspectives.
Klco JM; Kreisel FH; Zehnbauer BA; Kulkarni S; Hassan A; Frater JL
Am J Hematol; 2008 Dec; 83(12):901-7. PubMed ID: 18932238
[TBL] [Abstract][Full Text] [Related]
46. Microhomologies and interspersed repeat elements at genomic breakpoints in chronic myeloid leukemia.
Mattarucchi E; Guerini V; Rambaldi A; Campiotti L; Venco A; Pasquali F; Lo Curto F; Porta G
Genes Chromosomes Cancer; 2008 Jul; 47(7):625-32. PubMed ID: 18398823
[TBL] [Abstract][Full Text] [Related]
47. Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression.
Brazma D; Grace C; Howard J; Melo JV; Holyoke T; Apperley JF; Nacheva EP
Genes Chromosomes Cancer; 2007 Nov; 46(11):1039-50. PubMed ID: 17696194
[TBL] [Abstract][Full Text] [Related]
48. Advanced CML: therapeutic options for patients in accelerated and blast phases.
Shah NP
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S31-S36. PubMed ID: 18397679
[TBL] [Abstract][Full Text] [Related]
49. Hypomethylation of repeated DNA sequences in cancer.
Ross JP; Rand KN; Molloy PL
Epigenomics; 2010 Apr; 2(2):245-69. PubMed ID: 22121873
[TBL] [Abstract][Full Text] [Related]
50. Additional t(1;11)(q21;q23) with mixed lineage leukemia rearrangement in T-blastic crisis of a Ph-positive chronic myeloid leukemia.
Otero L; Moellmann AC; Pombo-de-Oliveira MS; Ornellas MH; Pires V; Bouzas LF; Fernandez Tde S
Eur J Haematol; 2007 Aug; 79(2):179-81. PubMed ID: 17608714
[No Abstract] [Full Text] [Related]
51. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
Strout MP; Schatz DG
Cancer Cell; 2009 Sep; 16(3):174-6. PubMed ID: 19732715
[TBL] [Abstract][Full Text] [Related]
52. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
53. An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia.
Ko TK; Javed A; Lee KL; Pathiraja TN; Liu X; Malik S; Soh SX; Heng XT; Takahashi N; Tan JHJ; Bhatia R; Khng AJ; Chng WJ; Sia YY; Fruman DA; Ng KP; Chan ZE; Xie KJ; Hoi Q; Chan CX; Teo ASM; Velazquez Camacho O; Meah WY; Khor CC; Ong CTJ; Soon WJW; Tan P; Ng PC; Chuah C; Hillmer AM; Ong ST
Blood; 2020 Jun; 135(26):2337-2353. PubMed ID: 32157296
[TBL] [Abstract][Full Text] [Related]
54. Deletion of chromosome 13: a rare form of cytogenetic evolution in blast phase of chronic myelogenous leukemia. Is there an association with favorable outcome?
Callera F; Rosa ES; Mulin CC
Leuk Res; 2007 May; 31(5):723-5. PubMed ID: 16919728
[No Abstract] [Full Text] [Related]
55. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
56. [New insight into DNA methylation in CML and its effect on clinical outcome--review].
Tang Y; Hu JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Dec; 16(6):1482-6. PubMed ID: 19099669
[TBL] [Abstract][Full Text] [Related]
57. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
[TBL] [Abstract][Full Text] [Related]
58. [Methylation of miR-378 in Chronic Myeloid Leukemia].
Wu DH; Yang J; Yang L; Wen XM; Guo H; Yao DM; Lin J; Zhang YY; Zhang M; Deng ZQ; Qian J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):61-5. PubMed ID: 26913395
[TBL] [Abstract][Full Text] [Related]
59. Enhanced expression and activity of DNA polymerase beta in chronic myelogenous leukemia.
Canitrot Y; Laurent G; Astarie-Dequeker C; Bordier C; Cazaux C; Hoffmann JS
Anticancer Res; 2006; 26(1B):523-5. PubMed ID: 16739313
[TBL] [Abstract][Full Text] [Related]
60. Chronic myelogenous leukemia, BCR-ABL1+.
Vardiman JW
Am J Clin Pathol; 2009 Aug; 132(2):250-60. PubMed ID: 19605820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
